LXEO
LXEO clinical trials: Lexeo Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Lexeo Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
LXEO on the catalyst calendar · LXEO registry changes
- Primary completion Nov 2028Sponsor estimatePhase 1NCT05400330Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseaseLexeo Therapeutics · Alzheimer DiseaseActive, not recruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2032Sponsor estimatePhase 2NCT07721025Study of LX2006 Gene Therapy in Friedreich Ataxia CardiomyopathyLexeo Therapeutics · Friedreich AtaxiaRecruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimateNo phase registeredNCT06865482Clinical Course Of Disease In Participants With FA-CMLexeo Therapeutics · Friedreich AtaxiaRecruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimatePhase 1/Phase 2NCT05445323Gene Therapy for Cardiomyopathy Associated With Friedreich's AtaxiaLexeo Therapeutics · Friedreich AtaxiaActive, not recruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2030Sponsor estimateNo phase registeredNCT07050160Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic VariantLexeo Therapeutics · Arrhythmogenic CardiomyopathyEnrolling by invitationLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06109181Gene Therapy for ACM Due to a PKP2 Pathogenic VariantLexeo Therapeutics · Arrhythmogenic CardiomyopathyActive, not recruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2024ActualPhase 1/Phase 2NCT03634007Gene Therapy for APOE4 Homozygote of Alzheimer's DiseaseLexeo Therapeutics · Alzheimer DiseaseCompletedLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimateNo phase registeredNCT06976606A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACMLexeo Therapeutics · Arrhythmogenic CardiomyopathyRecruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner